ANTIVIRAL ACTIVITY, SAFETY AND PHAMACOKINETICS OF MOZENAVIR (DMP 450), A NOVEL CYCLIC UREA PROTEASE INHIBITOR, IN COMBINATION WITH d4T AND 3TC IN TREATMENT-NAÏVE HIV-1 INFECTED PATIENTS (STUDY DMP-102)
SAFETY AND EFFICACY OF TIPRANAVIR, A NON-PEPTIDIC PROTEASE INHIBITOR, IN MULTIPLE PI-FAILURE PATIENTS (BI 1182.2)
A RANDOMISED, OPEN LABEL STUDY TO INVESTIGATE ABACAVIR ( ABC) AND LAMIVUDINE ( 3TC) AS ONCE DAILY (QD) COMPONENTS OF A TRIPLE COMBINATION REGIMEN (EPV40001).
PHASE II 24-WEEK DATA FROM STUDY AI424-008: COMPARATIVE RESULTS OF BMS-232632, STAVUDINE, LAMUVIDINE AS HAART FOR TREATMENT-NAÏVE HIV-INFECTED PATIENTS.
KALETRA VS. NELFINAVIR IN ANTIRETROVIRAL-NAIVE SUBJECTS: WEEK 60 COMPARISON IN A PHASE III, BLINDED, RANDOMIZED CLINICAL TRIAL
FINAL 12-MONTH RESULTS FROM THE COMBINE STUDY: A RANDOMIZED, OPEN, MULTICENTER TRIAL COMPARING COMBIVIR PLUS NELFINAVIR OR NEVIRAPINE IN NAIVE PATIENTS.
ANTIBODY PROTECTION OF MACAQUES AGAINST VAGINAL CHALLENGE WITH A PATHOGENIC R5 HIV-1/SIV CHIMERIC VIRUS REQUIRES COMPLETE NEUTRALIZATION OF VIRUS
IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A PRIME BOOST STRATEGY USING DNA-MVA HIV/SIV VACCINES IN MACAQUES.
IDENTIFICATION OF HIV-SPECIFIC CD4+ T CELLS IN PERIPHERAL BLOOD OF HIV-1- INFECTED INDIVIDUALS BY TETRAMERIC HLA-DR MOLECULES COVALENTLY COMPLEXED WITH PEPTIDES.
TOWARDS A MOLECULAR UNDERSTANDING OF THE BROAD NEUTRALIZING ACTIVITY OF THE HUMAN ANTI-GP120 ANTIBODY B12
ENHANCED EFFICACY OF VLP BASED DNA PRIME/PROTEIN BOOST IMMUNIZATION OF MACAQUES AGAINST PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS (SIV) USING IL-12 AND GM-CSF ADJUVANTS
REVERSION KINETICS OF A LIVE ATTENUATED SIV CAN BE IMPAIRED BY THE M184V MUTATION IN THE SIV RT
VIRAL LOAD, PERCENTAGE CD4 CELL COUNT AND SURVIVAL IN HIV MONOTYPIC AND DUAL INFECTIONS IN WEST AFRICA
CLINICAL COURSE OF HIV-INFECTED PATIENTS WITH DETECTABLE VIREMIA WHILE ON ANTIRETROVIRAL THERAPY
QUANTIFYING 'PARADOXICAL' CD4 RESPONSES AMONG A CLOSELY FOLLOWED COHORT OF PATIENTS INITIATING ANTIRETROVIRAL THERAPY
IMMUNE ACTIVATION IS A MAJOR CAUSE FOR CD4 DECLINE DURING HIV INFECTIONERMINING CD4 DECLINE
CCR5 HAPLOTYPES ASSOCIATED WITH ALTERED RATES OF HIV-1 VERTICAL TRANSMISSION AND PROGRESSION TO DISEASE IN CHILDREN
IN PATIENTS ON PROLONGED HAART, A SIGNIFICANT PART OF HIV-INFECTED CD4 T CELLS ARE SPECIFIC OF HIV ANTIGENS
THE RECTAL MUCOSA IS A SITE OF HIV-1 REPLICATION AND SHEDDING AND CD4+ T-CELL DEPLETION IN MEN WITH CHRONIC HIV-1 INFECTION
EARLY HIV-1 DNA LEVEL PREDICTS DISEASE PROGRESSION AND DEATH INDEPENDENTLY OF HIV-RNA LEVEL AND CD4 CELL COUNT.
PERSISTENCE OF LOW-GRADE HIV-1 REPLICATION IN RESTING MEMORY T CELLS IN PERSONS INITIATING EARLY AND AGGRESIVE ANTIRETROVIRAL THERAPY
MONITORING INTRACELLULAR HIV1 REPLICATION IN BLOOD AND LYMPHOID TISSUE IN ANTIRETROVIRAL NAIVE SUBJECTS RECEIVING AMPRENAVIR (APV), ABACAVIR (ABC), AND 3TC (COLA3003 STUDY)
PERSISTENT DEPLETION OF CD4 + T CELLS IN LYMPHOID TISSUES AMONG PATIENTS RANDOMIZED TO TRIPLE NUCLEOSIDE VS. PROTEASE OR NONNUCLEOSIDE CONTAINING REGIMENS IN THE ATLANTIC STUDY
DISCREPANCIES BETWEEN VIRAL LOAD, RESISTANCE PROFILE AND PROTEASE INHIBITORS' CONCENTRATION IN HIV-1 RESERVOIRS AND SANCTUARIES
VIROLOGICAL RESPONSE IN RESERVOIRS IN HIV-INFECTED NAIVE PATIENTS TREATED WITH COMBIVIR PLUS NELFINAVIR (CNF) OR NEVIRAPINE (CNR).
THERAPEUTIC DRUG MONITORING (TDM) OF NELFINAVIR (NFV) AND INDINAVIR (IDV) IN TREATMENT-NAIVE PATIENTS IMPROVES THERAPEUTIC OUTCOME AFTER 1 YEAR: RESULTS FROM ATHENA
EFFECTS OF PROLONGED DISCONTINUATION OF SUCCESSFUL ANTIRETROVIRAL THERAPY.
CLINICAL AND IMMUNOLOGIC OUTCOMES ACCORDING TO DIFFERENT LEVELS OF VIROLOGIC SUPPRESSION (VS) AFTER UNDETECTABILITY ON HAART
DURATION OF ANTIRETROVIRAL ADHERENCE PREDICTS BIOLOGIC OUTCOMES IN CLINICAL TRIALS
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS
INCIDENCE OF HEPATOTOXICITY AND MORTALITY IN 21 ADULT ANTIRETROVIRAL TREATMENT TRIALS
ANALYSES OF FOUR KEY CLINICAL TRIALS TO ASSESS THE RISK OF HEPATOTOXICITY WITH NEVIRAPINE: CORRELATION WITH CD4+ LEVELS, HEPATITIS B& C SEROPOSITIVITY, AND BASELINE LIVER FUNCTIONS TESTS.
HEPATIC AND CUTANEOUS TOXICITY ATTRIBUTED TO NEVIRAPINE (NVP)
STI VS. CONTINUOUS HAART DURING CHRONIC HIV INFECTION
EVALUATION OF A TRIPLE COMBINATION REGIMEN CONTAINING ENTERIC COATED DIDANOSINE ADMINISTERED ONCE-DAILY
A RANDOMIZED STUDY OF TREATMENT SIMPLIFICATION WITH NEVIRAPINE (NVP) OR EFAVIRENZ (EFV) IN PATIENTS RESPONDING TO A PROTEASE INHIBITOR(PI) BASED COMBINATION.
HIV-NAT 001.3: The safety, efficacy and pharmacokinetics (PK) of 1,600 mg saquinavir (soft-gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV, 100 mg) in a once-daily (qd) dosing regimen in HIV-1-infected Thai patients.
CONTINUED INDINAVIR (800 mg TID) VERSUS SWITCHING TO INDINAVIR+RITONAVIR (800/100 mg BID) IN HIV PATIENTS HAVING ACHIEVED VIRAL LOAD SUPPRESSION. A RANDOMIZED STUDY:THE BID EFFICACY AND SAFETY TRIAL (BEST)
GREATER SUPPRESSION OF CD8 ACTIVATION WITH 4 VS 3 DRUGS IN EARLY STAGES OF PRIMARY HIV INFECTION (PHI) DESPITE SIMILAR PLASMA VIROLOGICAL DECAY RATES.
DIFFERENCES IN VIROLOGIC SUPPRESSION AMONG MEN AND WOMEN ENROLLED IN A POPULATION-BASED ANTIRETROVIRAL DRUG TREATMENT PROGRAM
ABACAVIR/COMBIVIR (ABC/COM) IS COMPARABLE TO INDINAVIR/COMBIVIR IN HIV-1 INFECTED ANTIRETROVIRAL THERAPY NAIVE ADULTS: PRELIMINARY RESULTS OF A 48-WEEK OPEN LABEL STUDY (CNA3014)
ANTIRETROVIRAL THERAPY REDUCES THE RISK OF TUBERCULOSIS IN A HIGH PREVALENCE SETTING
HIV-INFECTED INTRAVENOUS DRUG USERS ARE AT HIGH RISK OF ANAL SQUAMOUS INTRAEPITHELIAL LESIONS RELATED TO HPV INFECTION
ORAL SHEDDING AND PROPAGATION OF HHV-8 IN PHARYNGEAL LYMPHOID TISSUES: POTENTIAL COFACTOR ROLE OF HIV
NON-HODGKIN LYMPHOMA (NHL) AMONG HIV-INFECTED PATIENTS IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
QST-DIH -RANTES: A NOVEL CCR5 LIGAND WITH POTENT ANTI-HIV ACTIVITY
PHENOTYPIC AND ANTIGENIC PROPERTIES ASSOCIATED WITH PATHOGENIC R5-TROPIC SHIVSF162P3
EXPRESSION OF CXCR4 AND SDF-1 IN PERIPHERAL T-CELLS AND LYMPH NODES.
POTENT ANTI-HIV CHEMOKINE ANALOGUES PRODUCED THROUGH A PHAGE DISPLAY SELECTION STRATEGY.
SENSITIVITY OF HIV-1 TO FUSION INHIBITORS IS MODULATED BY CORECEPTOR SPECIFICITY AND INVOLVES DISTINCT REGIONS OF GP41
MECHANISMS FOR STIMULATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 REPLICATION BY AOP-RANTES
LONGITUDINAL INTERPLAY OF CD8+ T-CELL RESPONSES AND THE HIV-1 DERIVED P17 EPITOPE THEY RECOGNIZE DURING CHRONIC HIV-1 INFECTION
PARTIAL RESTAURATION ON HIV-SPECIFIC CD4 T CELL RESPONSES WITH DENDRITIC CELLS.
IMPACT OF IL-7 ON ADULT HUMAN THYMIC SUBSETS
ANALYSIS OF T-LYMPHOCYTE TURNOVER RATES USING NOVEL MODELS FOR THE STUDY OF DEUTERATED GLUCOSE
"LONG-TERM MEMORY" AND "EFFECTOR MEMORY" CD4 PHENOTYPE BASED ON EXPRESSION OF CD62L AND CD45-ISOFORMS PREDICTS PATTERNS OF CELL DIVISION AND DIFFERENTIATION
A NOVEL HIV-1 TRANSGENIC RAT MODEL OF HIV-NEPHROPATHY (HIVAN)
INFLUENCE OF ITAM MOTIF OF CHIMERIC SIMIAN/HUMAN IMMUNODEFICENCY VIRUS SHIVSBG-NEFYE ON VIRULENCE IN CHINESE RHESUS MACAQUES
RELATIVE DYNAMICS OF SIV REPLICATION AND IMMUNE RECOGNITION: DELAYED INFILTRATION OF ANTI-SIV CTLS ALLOWS VIRAL ESCAPE
EARLY AND PERSISTENT HEMATOPOIESIS FAILURE IN SHIV INFECTED MACAQUES DESPITE EFFICIENT HAART
CONSEQUENCES ON IMMUNE FUNCTIONS OF EARLY POST-EXPOSURE PROPHYLAXIS WITH HAART IN THE MODEL OF SHIV INFECTED MACAQUES.
ROLE OF CD154 SIGNALLING DURING INFECTION OF MACAQUES WITH SIV
SHORT-TERM IMMUNO-SUPPRESSIVE THERAPY WITH PREDNISOLONE IN HIV-1-INFECTED PATIENTS RECEIVING ABACAVIR WITH OR WITHOUT NEVIRAPINE
EFFECT OF NUCLEOSIDE (NRTI) INTENSIFICATION ON PREVALENCE OF MORPHOLOGIC ABNORMALITIES (MOAS) AT YEAR 4 OF RITONAVIR (RTV) PLUS SAQUINAVIR (SQV) THERAPY IN AN HIV -INFECTED COHORT
COMBINED ANTIRETROVIRAL THERAPY CAUSES CARDIOMYOPATHY
MITOCHONDRIAL DNA DEPLETION IN HIV+ PATIENTS WITH SYMPTOMATIC NUCLEOSIDE RELATED MITOCHONDRIAL TOXICITY.
A RANDOMISED TRIAL OF THYMIDINE ANALOGUE WITHDRAWAL IN LIPOATROPHIC HIV PATIENTS, VIROLOGICALLY CONTROLLED ON PROTEASE SPARING THERAPY - THE PIILR EXTENSION STUDY.
ILSTIM (ANRS 082) - INTERLEUKIN 2 (IL2) ACCELERATES CD4 CELLS RECONSTITUTION IN PATIENTS WITH CD4 <200/MM3 DESPITE EFFECTIVE HAART.
INTERMITTENT IL-2 ADMINISTRATION IN HIV INFECTED PATIENTS LEADS TO A DECREASE IN CD4+ T CELL TURNOVER RATES
ADJUVANT SCIL2 INCREASES THYMIC PRODUCTION IN PATIENTS WITH ADVANCED HIV INFECTION UNDER ANTIRETROVIRAL THERAPY
QUALITY OF LIFE IN A RANDOMIZED CONTROLLED TRIAL OF HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY WITH INTERMITTENT IL-2 BY IV OR SC ROUTES IN PATIENTS WITH CD4 50-350 CELLS/MM3 (ACTG 328).
SAFETY AND ACTIVITY OF RECOMBINANT HUMAN INTERLEUKIN-12 (RHIL-12) IN HIV+ PATIENTS
HYDROXYUREA THERAPY SPARES THE NAIVE T CELL COMPARTMENT IN PATIENTS TREATED WITH ANTIRETROVIRAL DRUGS: THE 3D STUDY
EFFECT OF IL-2 ON RESPONSES TO HIV AND TETANUS IMMUNIZATION: RESULTS OF ACTG 5046S
INTERLEUKIN-2 THERAPY IN HIV-1 INFECTED ARV NAIVE PATIENTS: EFFECT ON T CELL ACTIVATION.
VIROLOGICAL AND IMMUNOLOGICAL EFFECTS OF DISCONTINUATION OF ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS WITH VIROLOGICAL FAILURE AND A CD4 COUNT ABOVE 500 CELLS/ML
IMPACT OF TREATMENT INTERRUPTION ON PLASMA VIRAL LOAD, CD4 COUNT AND VIRTUAL PHENOTYPES_ (VIRCO) IN HIV PATIENTS WHO FAILED MULTIPLE COURSES OF ANTIRETROVIRAL THERAPY.
INDINAVIR INTENSIFICATION FOR SALVAGE THERAPY IN HIV INFECTED PATIENTS HEAVILY PRE-TREATED: INDINAVIR/RITONAVIR BID 800/200 MG VS 400/400 MG
PRELIMINARY RESULTS OF A RANDOMIZED TRIAL COMPARING D4T/DDI/ABACAVIR/EFAVIRENZ TO THE SAME COMBINATION PLUS HYDROXYUREA WITH OR WITHOUT IL-2 AS SALVAGE REGIMENS (THE HYDILE STUDY)
MULTIPLE DRUG RESCUE THERAPY (MDRT) WITH AND WITHOUT LOPINAVIR/R (LPV/R)
ANTIVIRAL ACTIVITY AND TOLERABILITY OF PEG-INTRON IN HIV PATIENTS FAILING HAART
ASSEMBLY AND MOVEMENT OF GAG/GAG-POL COMPLEXES IN HIV-INFECTED CELLS.
THE TRIPEPTIDES GPG-NH2 AND ALG-NH2 INTERFERE WITH HIV-1 BUDDING AND CAPSID ASSEMBLY: A NEW STRATEGY FOR ANTIVIRAL THERAPY
CD147 FACILITATES HIV-1 INFECTION BY INTERACTING WITH VIRUS ASSOCIATED CYCLOPHILIN A
INTERFERON REGULATORY FACTORS REGULATE ACTIVATION OF HIV-1 VIA PHYSICAL AND FUNCTIONAL INTERACTIONS WITH TAT
EVOLVING PATTERNS OF HIV-1 RESISTANCE TO ANTIRETROVIRAL AGENTS IN NEWLY INFECTED INDIVIDUALS
EVOLUTION OF HIV-1 RESISTANCE MUTATIONS TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) FOLLOWING WITHDRAWAL
BOTH ANTIRETROVIRAL DRUG LEVELS AND DRUG RESISTANCE ARE ASSOCIATED WITH SHORT-TERM VIROLOGIC RESPONSES TO SUBSEQUENT DRUG REGIMENS IN CPCRA 046 (GART STUDY)
THE VIRTUAL PHENOTYPE IS A SUPERIOR INDEPENDENT PREDICTOR OF CLINICAL RESPONSE THAN GENOTYPING WITH A COMMON RULES BASED INTERPRETATION
IMPACT OF TREATMENT GUIDED BY PHENOTYPIC OR GENOTYPIC RESISTANCE TESTS ON THE RESPONSE TO ANTIRETROVIRAL THERAPY (ART): FINAL ANALYSIS OF THE NARVAL TRIAL (ANRS 088)
CCTG 575: A RANDOMIZED, PROSPECTIVE STUDY OF PHENOTYPE TESTING (PHENO) VERSUS STANDARD OF CARE (SOC) FOR PATIENTS FAILING ANTIRETROVIRAL THERAPY (ARV)
GENOTYPIC ANALYSES AND HIV RNA RESPONSES IN PATIENTS AFTER 96 WEEKS OF TENOFOVIR DF (TDF) THERAPY
COMPARISON OF THE EMERGENCE OF GENOTYPIC RESISTANCE OVER 48 WEEKS OF THERAPY WITH ABT-378/R (KALETRAT) OR NELFINAVIR PLUS D4T/3TC
MATERNAL VIRAL DIVERSITY, V3 ANTIBODIES AND THE VERTICAL TRANSMISSION OF HIV-1 SUBTYPE C.
EFFECT OF HIV-1 RNA LEVELS, CD4+LYMPHOCYTES AND CHEMOKINE RECEPTOR GENE POLYMORPHISMS ON THE RESPONSE TO HAART IN HIV-1 INFECTED CHILDREN
EARLY SPREAD OF HIV-1 B/F RECOMBINANT INTERSUBTYPE IN CHILDREN BORN TO INFECTED MOTHERS IN ARGENTINA
HOST GENETIC AND IMMUNLOGIC RESPONSES MEDIATING LONG TERM SURVIVAL IN HIV-1-INFECTED AFRICAN CHILDREN
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN INFANTS UPON IMMUNE RECONSTITUTION
ATYPICAL HIV-1 ASSOCIATED HEMOLYTIC UREMIC SYNDROME (HIV-HUS) AND HIV-HELPP SYNDROME IN CHILDREN
VIRAL INFECTIVITY, REPLICATION, AND QUASISPECIES EVOLUTION OF HIV-1 IN PRIMARY INFECTION
<< Previous
Next >>